WebDoctor Encyclopedia

Adnexal carcinomas Skin

Pilomatrix carcinoma

Pilomatrix carcinoma is a rare skin cancer of hair follicle matrix cells, the malignant counterpart of the benign pilomatricoma. It usually appears as a firm lump on the head or neck of an older man and is best treated with wide excision or Mohs surgery.

Medically reviewed Last reviewed October 20, 2026

What is pilomatrix carcinoma?

Pilomatrix carcinoma is a rare skin cancer that starts in the hair follicle. It develops from matrix cells, the rapidly dividing cells at the base of the follicle that normally produce the hair shaft. It is also called pilomatrical carcinoma or malignant pilomatricoma.

It is the cancerous counterpart of pilomatricoma, a common benign lump that usually affects children and young adults. Pilomatrix carcinoma, by contrast, mostly affects middle-aged and older adults, and men much more often than women. It may arise on its own or, less commonly, within a previous pilomatricoma (Riva et al., 2025).

The tumour usually appears as a firm, painless lump in or under the skin, most often on the back of the neck, scalp or face. It is frequently mistaken for a cyst or another harmless lump, so the diagnosis is often made only after removal.

Pilomatrix carcinoma tends to grow into surrounding tissue and come back after surgery if not completely removed. Spread to other parts of the body is uncommon but possible, most often to the lungs (Jones et al., 2018). Complete surgical removal with clear margins is the key treatment.

1. Key facts at a glance

Feature Details
Type of cancer Malignant adnexal (skin appendage) tumour of hair follicle matrix cells
Also called Pilomatrical carcinoma; malignant pilomatricoma
How common Very rare; a few hundred cases reported
Typical age Mostly 40-80; median around 60
Sex Men affected about 2-3 times as often as women
Main sites Back of the neck, scalp, face, upper back and arms
Main treatment Wide excision or Mohs micrographic surgery
Recurrence Common after standard excision
Outlook Good when fully removed; poorer if it spreads

Pilomatricoma versus pilomatrix carcinoma

Feature Pilomatricoma (benign) Pilomatrix carcinoma (malignant)
Usual age Children and young adults Older adults
Growth Slow, stable Can grow faster; may ulcerate
Edges under the microscope Well defined Infiltrative and irregular
Cell division Low High, with abnormal forms
Necrosis Uncommon Common
Recurrence after removal Rare Frequent
Spread Never Possible

Forms of pilomatrix carcinoma

Form Notes
De novo Arises without a known previous lump; the most common situation
Arising in a pilomatricoma Develops in a pre-existing benign lesion or its scar
Recurrent Returns at the original site, often after incomplete excision
Sarcomatoid variant Very rare; contains spindle cells

3. Causes and risk factors

The cause is not fully understood. Most tumours carry changes in the CTNNB1 gene, which makes the protein beta-catenin. Beta-catenin is part of the Wnt signalling pathway, which controls hair follicle growth. When it is switched on permanently, matrix cells keep dividing.

Factor Notes
Older age Most patients are over 40
Male sex Clearly more common in men
Fair skin Most reported patients are white
Previous pilomatricoma Rarely, carcinoma develops in or near an old lesion
Incomplete excision Raises the risk of recurrence

The gene changes occur only in the tumour and are not inherited. Sun exposure has not been clearly linked with this tumour.

4. How does it look

On the skin

Feature Description
Shape A firm, rounded nodule in the deeper skin
Size Often 1-4 cm, sometimes much larger
Colour Skin-coloured, red, purple or bluish
Surface Usually smooth; may ulcerate or bleed
Feel Hard, sometimes stony because of calcium deposits
Mobility May become fixed to deeper tissues
Pain Usually painless

On scans

Ultrasound may show a solid nodule with calcified areas. MRI or CT is used for large or recurrent tumours to assess depth and involvement of muscle, bone or nerves. CT of the chest or PET-CT looks for spread to lymph nodes and lungs in higher-risk cases.

Under the microscope

Feature Description
Basaloid cells Sheets of small, dark matrix-type cells
Ghost (shadow) cells Pale cells that have lost their nucleus, typical of matrix tumours
Calcification Common
Mitoses Numerous, including abnormal forms
Necrosis Frequently present
Growth pattern Asymmetric and infiltrative
Stains Nuclear beta-catenin and LEF1 positive

The pathologist looks at the whole lesion, because a small biopsy may contain only benign-looking areas.

Sites of pilomatrix carcinoma

Site Notes
Back of the neck One of the most frequent sites
Scalp Common; may be hidden by hair
Face, including cheeks and around the ear Mohs surgery is often preferred to spare tissue
Upper back and shoulders Frequent in adults
Arms and legs Less common

5. Symptoms

Common symptoms

  • A firm lump in or under the skin, especially on the back of the neck, scalp or face
  • A lump that has grown over months
  • A lump that feels hard or gritty
  • Redness or bluish discolouration of the overlying skin

Less common symptoms

Symptom What it may mean
Ulceration or bleeding Advanced local growth
Pain or tenderness Inflammation or deeper invasion
Lump returning at a scar Local recurrence
Enlarged lymph nodes Regional spread
Cough or breathlessness Rarely, spread to the lungs

When to seek medical advice

See a doctor about any new, growing or hard skin lump in an adult, particularly if it ulcerates, bleeds or reappears after removal. Many skin lumps are harmless, but persistent firm ones should be examined.

6. Diagnosis

Test Purpose
Skin examination Assesses the lump and nearby lymph nodes
Excision or incisional biopsy Provides tissue for diagnosis
Histopathology Confirms carcinoma and checks margins
Immunohistochemistry Supports the diagnosis and excludes look-alikes
Ultrasound of lymph nodes Checks for regional spread
CT or PET-CT For large, recurrent or high-risk tumours

Conditions that can look similar

Condition Notes
Epidermoid cyst Common harmless cyst; often the first clinical guess
Pilomatricoma Benign counterpart
Basal cell carcinoma Common skin cancer with basaloid cells
Merkel cell carcinoma Aggressive neuroendocrine skin cancer
Metastasis from another cancer Excluded with stains and scans

Staging

There is no dedicated staging system. Doctors describe the size and depth of the tumour, whether it has recurred, and whether there is spread to lymph nodes or distant organs.

7. Treatment

Treatment is usually led by a skin cancer team, including dermatologists, dermatological or plastic surgeons and oncologists.

Surgery

Option Notes
Wide local excision Removes the tumour with a margin of healthy tissue; the most common approach
Mohs micrographic surgery Removes the tumour in thin layers, checking every margin under the microscope; spares healthy tissue
Reconstruction Skin grafts or flaps for larger defects
Lymph node surgery If nodes are involved

A review of 101 published cases found no recurrences among 17 patients treated with Mohs surgery, compared with a recurrence rate of about 35% after standard excision, although follow-up was short (Riva et al., 2025).

Mohs surgery step by step

Step What happens
Local anaesthetic The area is numbed; you stay awake
First layer The visible tumour and a thin rim of tissue are removed
Mapping The tissue is marked and colour-coded so its position is known
Microscope check Every edge is examined while you wait, usually for about an hour
Further layers More tissue is removed only where tumour remains
Repair Once the margins are clear, the wound is stitched, grafted or left to heal

Mohs surgery is especially useful on the face, scalp and neck, where saving healthy skin matters for appearance and function. It is not available everywhere, and it may take most of a day.

Radiotherapy

Situation Role
Close or positive margins May lower the risk of recurrence
Tumours that cannot be removed For local control
Spread to lymph nodes Sometimes after node surgery
Painful metastases Symptom relief

Treatment of spread

There is no standard drug treatment. Chemotherapy has been tried in a few people with limited success. Treatment of metastatic disease is individualised, and clinical trials or molecular profiling of the tumour may be considered.

Side effects

Treatment Possible side effects
Excision Scarring, wound healing problems, numbness near the scar
Mohs surgery Longer procedure; small scar in most cases
Flaps or grafts Colour or contour differences
Radiotherapy Skin redness, hair loss in the treated area, tiredness

What treatment involves day to day

Stage What to expect
Excision or Mohs surgery Usually done under local anaesthetic as a day case
Larger reconstruction May need a general anaesthetic and a short hospital stay
Wound care Dressings and stitches removed after 1-2 weeks
Radiotherapy, if needed Daily weekday sessions for a few weeks

8. Outlook (prognosis)

Factor Effect on outlook
Complete removal with clear margins Good long-term control
Local recurrence Common; linked with a higher risk of spread (Herrmann et al., 2014)
Large or deeply invasive tumours Higher risk
Lymph node or lung spread Poorer outlook
Treatment at an experienced centre Helps ensure clear margins and appropriate follow-up

Most people who have the tumour completely removed do well. Because recurrence and later spread are possible, long-term follow-up is advised (Park, Wan and Khachemoune, 2025).

Why recurrence matters

Pilomatrix carcinoma sends thin, finger-like strands into the surrounding skin and fat. These strands can extend beyond what the surgeon can see or feel, so a standard excision may leave tumour behind.

When the cancer comes back, it often does so within the first two years, and each recurrence can be larger and more difficult to remove. A review of reported cases found that people whose tumour had recurred locally were more likely to develop metastases (Herrmann et al., 2014).

This is why surgeons aim for complete removal at the first operation, and why a second operation is often recommended if the margins are involved.

9. Follow-up

Follow-up Purpose
Skin and scar examination every 3-6 months at first Detects local recurrence early
Lymph node examination Checks the neck, armpits or groin
Imaging Ultrasound or chest CT for higher-risk tumours
Annual reviews later For at least 5 years

10. Living with pilomatrix carcinoma

  • Check your scar regularly and report any new lump
  • Keep follow-up appointments, even if you feel well
  • Protect healing scars from the sun to help them fade
  • Ask about scar treatments such as massage or silicone gel
  • Tell your doctor about any new lump elsewhere, including in the neck or armpit
  • Keep a copy of your pathology report, as it helps if you see a new specialist
  • Seek support from skin cancer charities and patient groups

11. Frequently asked questions

Question Answer
Is it the same as a pilomatricoma? No; pilomatricoma is benign, while pilomatrix carcinoma is its malignant form
Is it caused by the sun? No clear link with sun exposure has been shown
Is it inherited? No
Why did my lump come back? Small strands of tumour can remain at the margins after excision
Is Mohs surgery better? Early reports suggest fewer recurrences, but large studies are lacking
Will I need chemotherapy? Rarely; surgery is the main treatment
Can it spread? Occasionally, most often to the lungs or lymph nodes
How big a scar will I have? It depends on the size and site of the tumour; Mohs surgery often keeps scars smaller
Can it occur in children? Very rarely; lumps in children are almost always benign pilomatricomas

12. Questions to ask your care team

  • Were the margins clear?
  • Would Mohs surgery or further excision be suitable for me?
  • Do I need radiotherapy?
  • Should I have scans to check for spread?
  • How often will my follow-up be, and for how long?
  • What signs of recurrence should I look out for?
  • Is there a specialist skin cancer centre with experience of this tumour?

Resources

  1. Herrmann, J.L. et al. (2014) ‘Pilomatrix carcinoma: 13 new cases and review of the literature with emphasis on predictors of metastasis’, Journal of the American Academy of Dermatology, 71(1), pp. 38-43.
  2. Jones, C. et al. (2018) ‘Pilomatrix carcinoma: 12-year experience and review of the literature’, Journal of Cutaneous Pathology, 45(1), pp. 33-38.
  3. Park, A., Wan, L. and Khachemoune, A. (2025) ‘Pilomatrix carcinoma unveiled: a systematic review of clinical characteristics, pathogenesis, diagnostic puzzles, and management strategies’, Archives of Dermatological Research, 317(1), 278.
  4. Riva, H.R. et al. (2025) ‘Surgical treatment of pilomatrix carcinoma: a systematic review’, International Journal of Dermatology, 64(6), pp. 1021-1026.

Prepared by the editorial team, October 2026.